Genmab AS (MEX:GMABN) Cyclically Adjusted Revenue per Share: MXN455.69 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GMABN Genmab AS MEX:GMABN
93 GF Score
Price MXN5,000.66
GF Value MXN5,659.54
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted Revenue per Share?

Genmab AS MEX:GMABN 93 Cyclically Adjusted Revenue per Share is MXN455.69 as of Jun. 2026. GuruFocus rates MEX:GMABN with a GF Score™ of 93/100 and a GF Value™ of MXN5,659.54 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genmab AS's adjusted revenue per share for the three months ended in Jun. 2026 was MXN326.580. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN455.69 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted Revenue Growth Rate was 26.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 29.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 33.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genmab AS was 43.30% per year. The lowest was 29.50% per year. And the median was 36.00% per year.

As of today (2026-08-14), Genmab AS's current stock price is MXN5000.66. Genmab AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN455.69. Genmab AS's Cyclically Adjusted PS Ratio of today is 10.97.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 96.41. The lowest was 8.11. And the median was 45.29.


Genmab AS  (MEX:GMABN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5000.66/455.69
=10.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab AS was 96.41. The lowest was 8.11. And the median was 45.29.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genmab AS Cyclically Adjusted Revenue per Share Related Terms


Genmab AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted Revenue per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 199.51 250.38 265.98 482.15 500.86

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 528.02 460.33 500.86 506.17 455.69

MEX:GMABN vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PS Ratio falls into.


MEX:GMABN
93GF Score
Genmab AS MEX:GMABN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=326.58/122.9700*122.9700
=326.580

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 17.185 100.200 21.090
201612 41.055 100.300 50.334
201703 10.955 101.200 13.312
201706 34.642 101.200 42.094
201709 14.719 101.800 17.780
201712 52.962 101.300 64.292
201803 32.962 101.700 39.856
201806 25.104 102.300 30.176
201809 28.099 102.400 33.743
201812 58.501 102.100 70.459
201903 27.996 102.900 33.456
201906 35.973 102.900 42.989
201909 46.391 102.900 55.439
201912 129.592 102.900 154.868
202003 46.966 103.300 55.909
202006 288.529 103.200 343.802
202009 91.095 103.500 108.231
202012 120.181 103.400 142.927
202103 77.197 104.300 91.015
202106 95.256 105.000 111.558
202109 112.153 105.800 130.354
202112 113.723 106.600 131.187
202203 95.992 109.900 107.408
202206 135.361 113.600 146.526
202209 164.839 116.400 174.143
202212 250.670 115.900 265.961
202303 113.589 117.300 119.080
202306 158.443 116.400 167.386
202309 176.467 117.400 184.839
202312 187.981 116.700 198.081
202403 153.241 118.400 159.156
202406 220.047 118.500 228.348
202409 252.238 118.900 260.872
202412 297.331 118.900 307.509
202503 228.792 120.200 234.064
202506 280.951 120.700 286.235
202509 302.023 121.600 305.426
202512 301.826 121.200 306.234
202603 253.031 121.680 255.714
202606 326.580 122.970 326.580

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN455.69 mean?
Genmab AS (MEX:GMABN) has a Cyclically Adjusted Revenue per Share of MXN455.69 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted Revenue per Share too high?
Genmab AS's current Cyclically Adjusted Revenue per Share is MXN455.69. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted Revenue per Share of MXN455.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted Revenue per Share is MXN455.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,659.54, compared to a current price of MXN5,000.66 — trading 11.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN455.69. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Cyclically Adjusted Revenue per Share is MXN455.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (MEX:GMABN) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of MXN5,000.66 is trading 11.6% below its estimated GF Value™ of MXN5,659.54. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for MEX:GMABN:

  • Cyclically Adjusted Revenue per Share: MXN455.69
  • GF Value™: MXN5,659.54 vs. price of MXN5,000.66 (11.6% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for MEX:GMABN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN5,000.66
Price
MXN5,659.54
GF Value